메뉴 건너뛰기




Volumn 7, Issue 1, 2011, Pages 49-57

Assessing the general safety and tolerability of vildagliptin: Value of pooled analyses from a large safety database versus evaluation of individual studies

Author keywords

Dipeptidyl peptidase 4; Edema; Safety; Type 2 diabetes; Vildagliptin

Indexed keywords

ACARBOSE; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

EID: 79951607030     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S16925     Document Type: Article
Times cited : (42)

References (30)
  • 1
    • 27744540889 scopus 로고    scopus 로고
    • Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: Vildagliptin (LAF237) dose response
    • Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005;7:692-698.
    • (2005) Diabetes Obes Metab , vol.7 , pp. 692-698
    • Ristic, S.1    Byiers, S.2    Foley, J.3    Holmes, D.4
  • 2
    • 33745903093 scopus 로고    scopus 로고
    • Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes
    • Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res. 2006;38:423-428.
    • (2006) Horm Metab Res , vol.38 , pp. 423-428
    • Pratley, R.E.1    Jauffret-Kamel, S.2    Galbreath, E.3    Holmes, D.4
  • 3
    • 33847687205 scopus 로고    scopus 로고
    • Vildagliptin in drug-naive patients with type 2 diabetes: A 24-week, double-blind, randomized, placebocontrolled, multiple-dose study
    • Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebocontrolled, multiple-dose study. Horm Metab Res. 2007;39:218-223.
    • (2007) Horm Metab Res , vol.39 , pp. 218-223
    • Dejager, S.1    Razac, S.2    Foley, J.E.3    Schweizer, A.4
  • 4
    • 44949170696 scopus 로고    scopus 로고
    • Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycemia
    • Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycemia. Diabetes Obes Metab. 2008;10:675-682.
    • (2008) Diabetes Obes Metab , vol.10 , pp. 675-682
    • Scherbaum, W.A.1    Schweizer, A.2    Mari, A.3
  • 5
    • 38149137991 scopus 로고    scopus 로고
    • Characterization of the influence of vildagliptin on model-assessed {beta}-cell function in patients with type 2 diabetes and mild hyperglycemia
    • Mari A, Scherbaum WA, Nilsson PM, et al. Characterization of the influence of vildagliptin on model-assessed {beta}-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab. 2008;93:103-109.
    • (2008) J Clin Endocrinol Metab , vol.93 , pp. 103-109
    • Mari, A.1    Scherbaum, W.A.2    Nilsson, P.M.3
  • 6
    • 53549129604 scopus 로고    scopus 로고
    • Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia
    • Scherbaum WA, Schweizer A, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. 2008;10:1114-1124.
    • (2008) Diabetes Obes Metab , vol.10 , pp. 1114-1124
    • Scherbaum, W.A.1    Schweizer, A.2    Mari, A.3
  • 7
    • 34548118796 scopus 로고    scopus 로고
    • Comparison between vildagliptin and metformin to sustain reductions in HbA1c over one year in drug-naïve patients with type 2 diabetes
    • Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over one year in drug-naïve patients with type 2 diabetes. Diabet Med. 2007;24:955-961.
    • (2007) Diabet Med , vol.24 , pp. 955-961
    • Schweizer, A.1    Couturier, A.2    Foley, J.E.3    Dejager, S.4
  • 8
    • 55049142279 scopus 로고    scopus 로고
    • Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: Comparison with metformin
    • Göke B, Hershon K, Kerr D, et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res. 2008;40:892-895.
    • (2008) Horm Metab Res , vol.40 , pp. 892-895
    • Göke, B.1    Hershon, K.2    Kerr, D.3
  • 9
    • 71849095372 scopus 로고    scopus 로고
    • Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes
    • Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res. 2009;41:905-909.
    • (2009) Horm Metab Res , vol.41 , pp. 905-909
    • Foley, J.E.1    Sreenan, S.2
  • 10
    • 41749106662 scopus 로고    scopus 로고
    • Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: A 24-week, double-blind, randomized trial
    • Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med. 2008;25:435-441.
    • (2008) Diabet Med , vol.25 , pp. 435-441
    • Pan, C.1    Yang, W.2    Barona, J.P.3
  • 11
    • 33846694046 scopus 로고    scopus 로고
    • Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial
    • Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007;30:217-223.
    • (2007) Diabetes Care , vol.30 , pp. 217-223
    • Rosenstock, J.1    Baron, M.A.2    Dejager, S.3
  • 12
    • 65549109984 scopus 로고    scopus 로고
    • Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus
    • Rosenstock J, Niggli M, Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diab Obes Metab. 2009;11:571-578.
    • (2009) Diab Obes Metab , vol.11 , pp. 571-578
    • Rosenstock, J.1    Niggli, M.2    Maldonado-Lutomirsky, M.3
  • 13
    • 38149096290 scopus 로고    scopus 로고
    • Effects of the DPP-4 inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance
    • Rosenstock J, Foley JE, Rendell M, et al. Effects of the DPP-4 inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care. 2008;31:30-35.
    • (2008) Diabetes Care , vol.31 , pp. 30-35
    • Rosenstock, J.1    Foley, J.E.2    Rendell, M.3
  • 14
    • 33846905487 scopus 로고    scopus 로고
    • Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes
    • Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76:132-138.
    • (2007) Diabetes Res Clin Pract , vol.76 , pp. 132-138
    • Pi-Sunyer, F.X.1    Schweizer, A.2    Mills, D.3    Dejager, S.4
  • 15
    • 67649933635 scopus 로고    scopus 로고
    • Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: A 24-week, double-blind, randomized trial
    • Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab. 2009;11:804-812.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 804-812
    • Schweizer, A.1    Dejager, S.2    Bosi, E.3
  • 16
    • 9444285818 scopus 로고    scopus 로고
    • Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
    • Ahrén B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2874-2880.
    • (2004) Diabetes Care , vol.27 , pp. 2874-2880
    • Ahrén, B.1    Gomis, R.2    Standl, E.3
  • 17
    • 34147093268 scopus 로고    scopus 로고
    • Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
    • Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30:890-893.
    • (2007) Diabetes Care , vol.30 , pp. 890-893
    • Bosi, E.1    Camisasca, R.P.2    Collober, C.3
  • 18
    • 58149330590 scopus 로고    scopus 로고
    • Fifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
    • Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11:157-166.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 157-166
    • Ferrannini, E.1    Fonseca, V.2    Zinman, B.3
  • 19
    • 77955048324 scopus 로고    scopus 로고
    • Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglyceamic risk compared with glimepiride, with no weight gain: Results from a 2-year study
    • Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglyceamic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780-789.
    • (2010) Diabetes Obes Metab , vol.12 , Issue.9 , pp. 780-789
    • Matthews, D.R.1    Dejager, S.2    Ahren, B.3
  • 20
    • 77949356196 scopus 로고    scopus 로고
    • A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: A 52-week, randomized study
    • Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diab Med. 2010;27(3):318-326.
    • (2010) Diab Med , vol.27 , Issue.3 , pp. 318-326
    • Filozof, C.1    Gautier, J.F.2
  • 21
    • 37349054435 scopus 로고    scopus 로고
    • Efficacy and tolerability of vildagliptin vs pioglitazone when added to metformin: A 24-week, randomized, double-blind study
    • Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab. 2008;10:82-90.
    • (2008) Diabetes Obes Metab , vol.10 , pp. 82-90
    • Bolli, G.1    Dotta, F.2    Rochotte, E.3    Cohen, S.E.4
  • 22
    • 65549131200 scopus 로고    scopus 로고
    • Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin
    • Bolli G, Dotta F, Colin L, et al. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab. 2009;11:589-595.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 589-595
    • Bolli, G.1    Dotta, F.2    Colin, L.3
  • 23
    • 67949105103 scopus 로고    scopus 로고
    • Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
    • Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res. 2009;41:368-373.
    • (2009) Horm Metab Res , vol.41 , pp. 368-373
    • Goodman, M.1    Thurston, H.2    Penman, J.3
  • 24
    • 77957751894 scopus 로고    scopus 로고
    • Effect of metformin as add-on therapy to a low dose metformin
    • Filozof C, Schwartz S, Foley JE. Effect of metformin as add-on therapy to a low dose metformin. World J Diabetes. 2010;1:19-26.
    • (2010) World J Diabetes , vol.1 , pp. 19-26
    • Filozof, C.1    Schwartz, S.2    Foley, J.E.3
  • 25
    • 65449135133 scopus 로고    scopus 로고
    • Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
    • Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11:506-515.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 506-515
    • Bosi, E.1    Dotta, F.2    Jia, Y.3    Goodman, M.4
  • 26
    • 33846828660 scopus 로고    scopus 로고
    • Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: A randomized, placebocontrolled study
    • Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebocontrolled study. Diabetes Obes Metab. 2007;9:166-174.
    • (2007) Diabetes Obes Metab , vol.9 , pp. 166-174
    • Garber, A.J.1    Schweizer, A.2    Baron, M.A.3
  • 27
    • 33846827085 scopus 로고    scopus 로고
    • Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared to component monotherapy in patients with type 2 diabetes
    • Rosenstock J, Baron MA, Camisasca RP, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared to component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:175-185.
    • (2007) Diabetes Obes Metab , vol.9 , pp. 175-185
    • Rosenstock, J.1    Baron, M.A.2    Camisasca, R.P.3
  • 28
    • 54249106294 scopus 로고    scopus 로고
    • Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea
    • Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008;10:1047-1056.
    • (2008) Diabetes Obes Metab , vol.10 , pp. 1047-1056
    • Garber, A.J.1    Foley, J.E.2    Banerji, M.A.3
  • 29
    • 34247874561 scopus 로고    scopus 로고
    • Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
    • Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50:1148-1155.
    • (2007) Diabetologia , vol.50 , pp. 1148-1155
    • Fonseca, V.1    Schweizer, A.2    Albrecht, D.3
  • 30
    • 47049084841 scopus 로고    scopus 로고
    • Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus
    • Fonseca V, Baron M, Shao Q, Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res. 2008;40:427-430.
    • (2008) Horm Metab Res , vol.40 , pp. 427-430
    • Fonseca, V.1    Baron, M.2    Shao, Q.3    Dejager, S.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.